Results 41 to 50 of about 133,265 (260)

Kinetics of Circulating Plasma Cell-Free DNA in Paediatric Classical Hodgkin Lymphoma [PDF]

, 2016
Levels of plasma cell-free DNA (cfDNA) of a large series of children with classical Hodgkin lymphoma (cHL) were evaluated and analyzed at diagnosis and during chemotherapy treatment in relation with clinical characteristics.
Basso, Giuseppe, Buffardi, Salvatore, Burnelli, Roberta, Carraro, Elisa, Elia, Caterina, Farruggia, Piero, Mascarin, Maurizio, Mussolin, Lara, Pillon, Marta, Primerano, Simona, Sala, Alessandra, Vinti, Luciana   +11 more
core   +2 more sources

Cationic mRNA Lipid Nanoparticles for Ex Vivo NanoCAR‐T Cell Engineering

Advanced Science, EarlyView.
This study compares charge‑neutral and cationic lipidnanoparticles (LNPs) for ex vivo mRNA delivery to T cells, revealing distinctdependencies on medium composition and T cell activation. Where conventional LNPs benefit from ApoE‐dependent T cell targeting, cationic DOTAP‑modified LNPs mediate unspecific charge‑dependent transfection.
Laure Harinck, Stijn De Munter, Margo De Velder, Joline Ingels, Dominika Berdecka, Ine Lentacker, Winnok H. De Vos, Bart Vandekerckhove, Kevin Braeckmans, Koen Raemdonck   +9 more
wiley   +1 more source

Rapid onset of hypercalcemia from high-grade lymphoma in the setting of HIV-related immune reconstitution inflammatory syndrome. [PDF]

, 2019
Hypercalcemia in HIV patients has been previously reported, but 1,25-(OH)2 vitamin D-mediated hypercalcemia, due to increased activity of extrarenal 1-alpha hydroxylase, is rarely described with HIV-related infections or malignancies.
Bikle, Daniel, Kim, Sarah, Kim, Stephanie J, Peluso, Michael J, Shoback, Dolores, Wang, Yongmei   +5 more
core  

Tumor‐Induced Splenic Remodeling: Mechanisms of Systemic Immunosuppression and Emerging Therapeutic Opportunities

Advanced Science, EarlyView.
ABSTRACT Despite the transformative impact of cancer immunotherapies such as immune checkpoint blockade, durable clinical responses remain limited. Increasing evidence indicates that antitumor immunity is governed not only by the tumor microenvironment, but also by systemic immune regulation mediated by peripheral immune organs. Among these, the spleen
Yuehua Liu, Xiaoqian Nie, Xiaofei Gao
wiley   +1 more source

Spectrum of malignancies among the population of adults living with HIV infection in China: A nationwide follow-up study, 2008-2011. [PDF]

, 2019
BackgroundAlthough increasingly studied in high-income countries, there is a paucity of data from the Chinese population on the patterns of cancer among people living with HIV (PLHIV).MethodsWe conducted a nationwide follow-up study using routinely ...
Detels, Roger, He, Na, Mao, Yurong, McGoogan, Jennifer M, Tang, Houlin, Wu, Zunyou, Zhang, Zuo-Feng, Zhu, Weiming   +7 more
core   +2 more sources

Consumed by Abdominal Distention

Arthritis Care &Research, EarlyView.
Abimbola Fadairo‐Azinge, James Grenert, Brian Haas, Mary Margaretten   +3 more
wiley   +1 more source

Fixed‐Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis

American Journal of Hematology, EarlyView.
ABSTRACT Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. A subcutaneous (SC) formulation, aiming to improve patient safety and convenience, has been developed.
Nancy L. Bartlett, Laurie H. Sehn, Sarit Assouline, Pratyush Giri, John Kuruvilla, Stephen J. Schuster, Sung‐Soo Yoon, Keith Fay, Georg Hess, Martin Dreyling, Norma C. Gutierrez, Eva Cybulski, Fidelis Sabalvaro, Elicia Penuel, Vanda Teodoro, Samuel Tracy, Denison Kuruvilla, Joseph Chen, Volker Wiebking, Michael C. Wei, L. Elizabeth Budde   +20 more
wiley   +1 more source

The Broad Spectrum HDAC Inhibitor PCI-24781 Induces Caspase- and ROS-Dependent Apoptosis and is Synergistic with Bortezomib in Lymphoma [PDF]

, 2008
We investigated the cytotoxicity and biology of the novel broad-spectrum hydroxamic acid-based histone deacetylase inhibitor (HDACi), PCI-24781. PCI-24781 was studied alone and combined with bortezomib in Hodgkin lymphoma (L428) and non-Hodgkin's ...
Andrew Evens, Joseph Buggy, Kevin David, Lauren Mauro, Leo Gordon, Mint Sirisawad, Richard Miller, Savita Bhalla, Sheila Prachand, Sriram Balasubramanian   +9 more
core   +1 more source

Single Cell RNA Transcriptomics of Mantle Cell Lymphoma Reveals the Presence of Treatment‐Resistant Subclones at the Time of Diagnosis

American Journal of Hematology, EarlyView.
ABSTRACT Mantle cell lymphoma (MCL) is a B‐cell malignancy with a chronically relapsing clinical course and pronounced genetic heterogeneity. To investigate the clonal dynamics underlying early disease relapse, we performed single‐cell RNA sequencing of paired tumor samples collected at diagnosis and at first relapse. Inference of copy number variants (
Dmitry Manakov, Magdalena Klanova, Michal Kolar, Robert Ivanek, Florian Geier, Julien Roux, Tomas Zikmund, Lucie Winkowska, Eva Kriegova, Jirina Manakova, Liliana Tuskova, Silvia Spanikova, Alexandra Scasna, Marek Trneny, Pavel Klener   +14 more
wiley   +1 more source

Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma [PDF]

, 2016
Key Points Combining phosphatidylinositol-3-kinase δ inhibition with rituximab, bendamustine, or both is feasible and active in relapsed iNHL.
Barrientos, Jacqueline C., Boccia, Ralph V., Boyd, Thomas E., Coutre, Steven E., de Vos, Sven, Flinn, Ian W., Fowler, Nathan H., Furman, Richard R., Godfrey, Wayne R., Kim, Yeonhee, Leonard, John P., Rai, Kanti R., Schreeder, Marshall T., Sharman, Jeff P., Wagner-Johnston, Nina D.   +14 more
core   +2 more sources